Welcome to our dedicated page for Cellebrite Di news (Ticker: CLBT), a resource for investors and traders seeking the latest updates and insights on Cellebrite Di stock.
Cellebrite DI Ltd. (NASDAQ: CLBT) generates a steady flow of news related to digital investigations, AI-powered analytics and public safety technology. As a global provider of digital investigative and intelligence solutions for public safety organizations, intelligence agencies, defense organizations and enterprises, the company frequently issues updates on its software platform, strategic initiatives and regulatory milestones.
News about Cellebrite often covers product and platform innovation, including releases that expand its Digital Investigation Platform. Recent announcements have highlighted enhancements to its flagship digital forensics solution, Inseyets, the expanded and reimagined Guardian suite for investigations and analytics, and the introduction of Guardian Investigate, a SaaS-based investigative solution that uses agentic AI to analyze multiple evidence types. Updates also describe new deployment options such as AWS GovCloud for Pathfinder and developments in the Cellebrite Government Cloud.
Investors and practitioners following CLBT news will also see corporate and strategic developments, such as the agreement and subsequent completion of the Corellium acquisition, which adds Arm-based mobile virtualization capabilities for security research and testing. Other coverage includes leadership changes, like the appointment of a new chief executive officer and chief financial officer, and governance events such as shareholder meeting outcomes.
Cellebrite’s news flow additionally features public sector and compliance milestones, including progress toward FedRAMP High authorization for its government cloud environment with sponsorship from the U.S. Department of Justice, and partnerships that support investigations into crimes against children. For ongoing insight into how Cellebrite’s technology, customer relationships and regulatory posture evolve, readers can review this CLBT news page regularly for the latest press releases and official updates.
Cellebrite (NASDAQ: CLBT) released its 2026 Industry Trends Report surveying 1,200 practitioners across 63 countries. Key findings: 97% cite smartphones as the top source of digital evidence (up 24 points from 2024), 95% say digital evidence raises solvability, and 65% expect AI to accelerate investigations.
Cloud receptiveness rose to 42%, though two-thirds still share evidence via physical media, creating custody risks. Guardian platform saw triple-digit YoY growth in customers, users and data stored in 2025.
Cellebrite (NASDAQ: CLBT) announced it will report fourth-quarter and fiscal year 2025 financial results before U.S. markets open on Wednesday, February 11, 2026. A live conference call and webcast to review Q4 2025 results and discuss the company’s 2026 outlook will follow at 8:30 a.m. ET the same day.
Call-in numbers, conference ID CLBTQ425, and live webcast links are provided; historical financial tables and supplemental data will be posted to the company’s quarterly results page on the investor relations website.
Cellebrite (NASDAQ: CLBT) completed the acquisition of Corellium on Dec 2, 2025, combining Corellium’s Arm-based virtualization with Cellebrite’s AI-powered digital investigation platform.
The transaction value was $170 million (including $150 million cash at closing, $20 million converted to equity, and up to $30 million in performance-based cash over two years). Corellium CTO Chris Wade joined Cellebrite as CTO. CFIUS permitted closing under a negotiated national security agreement pending formal agency execution. Cellebrite said one month of Corellium results will not materially affect 2025 outlook.
Cellebrite (NASDAQ: CLBT) reported third-quarter 2025 results with ARR $439.8M (+19%) and revenue $126.0M (+18%). Subscription revenue reached $112.7M (+21%) and recurring revenue NRR was 117%. GAAP net income was $20.2M; non-GAAP net income was $36.9M. Adjusted EBITDA was $37.7M with a 29.9% margin. Management reiterated full-year 2025 targets (ARR $460M–$475M; revenue $470M–$475M) and Q4 revenue guidance of $123M–$128M. Guidance excludes any contribution from the pending Corellium acquisition. The company highlighted product releases (Autumn 2025), Guardian Investigate SaaS (GA), and leadership hire for general counsel and compliance.
Cellebrite (Nasdaq: CLBT) announced on Oct 30, 2025 the appointment of Holly Windham as General Counsel and Chief Compliance Officer. She will oversee all legal and compliance matters and support efforts to ensure appropriate global use of Cellebrite technology. Ms. Windham succeeds Ayala Berler Shapira.
Ms. Windham previously served as Chief Legal Officer and Board Secretary at Self Financial, which serves more than 1.7 million consumers, and held multiple senior roles at Rackspace Technology, a $3 billion+ multi-cloud company where she led a team of 180 and participated in IPO and M&A activity exceeding $1 billion. She holds a J.D. from Pepperdine and a B.A. from Southwestern Oklahoma State University.
Cellebrite (NASDAQ: CLBT) announced that actor and advocate Terry Crews will headline its C2C User Summit 2026, taking place April 13–17, 2026 at the Washington, D.C. Marriott Marquis.
The second annual summit gathers public safety and private sector digital investigation professionals for immersive training, thought leadership, networking and qualified professional credit. Crews will share personal lessons on resilience and advocacy against human trafficking and abuse. The event features the Digital Justice Awards (Justys) and will showcase Cellebrite innovations including the newly added Corellium technology.
Cellebrite (NASDAQ: CLBT) will report its third-quarter 2025 financial results after the U.S. market close on Wednesday, November 12, 2025.
The company will host a live conference call and webcast at 5:00 p.m. ET the same day to review Q3 2025 results and discuss its full-year 2025 outlook. Participants can join via the provided call-in numbers or the live webcast, and historical financial tables and supplemental data will be posted on the quarterly results section of the company investor relations website.
Cellebrite (NASDAQ: CLBT) released its Autumn 2025 Release on Oct 15, 2025, adding agentic AI, cloud options and Arm-based device virtualization via a reseller agreement with Corellium while the company advances the acquisition process.
Key updates include Guardian Investigate (limited production with design partners; general availability scheduled for early 2026), expanded Guardian SaaS offerings with a new EU data-residency region, expanded Android/iOS collection via Inseyets, an AWS GovCloud deployment option for Pathfinder, and Corellium mobile vulnerability and app-security tooling now subscribed by multiple defense and intelligence customers in EMEA and APAC.
ValueAct Capital filed a Large Shareholding Report on October 9, 2025, disclosing an approximate 7.8% stake in Sun Corp (TSE:6736). ValueAct said it respects Sun’s businesses and highlighted Sun’s historical sponsorship of Cellebrite (NASDAQ:CLBT). ValueAct indicated it plans further engagement with management of both Sun and Cellebrite and expressed a belief that Sun is positioned to maximize the value of its Cellebrite investment, which ValueAct says could benefit stakeholders of both companies.
Cellebrite (NASDAQ: CLBT), a leader in Digital Investigative solutions, reported strong Q2 2025 results with revenue growing 18% to $113.3 million and ARR up 21% to $418.9 million. The company announced the appointment of Thomas E. Hogan as CEO and David Barter as CFO.
Key financial highlights include subscription revenue of $103.0 million (up 21% YoY), GAAP net income of $19.5 million, and adjusted EBITDA of $27.9 million with a 24.6% margin. The company announced plans to acquire Corellium for $170 million and received U.S. Department of Justice sponsorship for FedRAMP High authorization.
For full-year 2025, Cellebrite expects revenue between $465-475 million and ARR of $460-475 million, with adjusted EBITDA margin of 25-26%.
FAQ
What is the current stock price of Cellebrite Di (CLBT)?
What is the market cap of Cellebrite Di (CLBT)?
